MedPath

LEUKO LABS, INC.

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

1 Phases

Not Applicable:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (1 trials with phase data)• Click on a phase to view related trials

Not Applicable
1 (100.0%)

Pivotal Study to Validate a Novel System to Non-Invasively Detect Severe Neutropenia

Not yet recruiting
Conditions
Diffuse Large B Cell Lymphoma
Multiple Myeloma
First Posted Date
2024-03-21
Last Posted Date
2024-10-09
Lead Sponsor
Leuko Labs, Inc.
Target Recruit Count
210
Registration Number
NCT06323447

Usability, Adherence and Diagnostic Performance of PointCheck in Pediatric Population

Completed
Conditions
Hematologic Malignancy
First Posted Date
2021-05-17
Last Posted Date
2025-03-11
Lead Sponsor
Leuko Labs, Inc.
Target Recruit Count
46
Registration Number
NCT04889937
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Study to Evaluate the Usability of PointCheck

Completed
Conditions
Neoplasms
Chemotherapy-induced Neutropenia
First Posted Date
2020-06-25
Last Posted Date
2023-08-22
Lead Sponsor
Leuko Labs, Inc.
Target Recruit Count
94
Registration Number
NCT04448314
Locations
🇪🇸

Hospital Universitari Dexeus. Grupo Quirónsalud, Barcelona, Spain

🇪🇸

Breast Unit. Oncology Department. 12 Octubre Hospital, Madrid, Spain

🇪🇸

Hospital Universitario 12 de Octubre, Madrid, Spain

PC001- A Study to Evaluate the Usability of PointCheck

Not Applicable
Recruiting
Conditions
Neoplasms
Neutropenia
First Posted Date
2020-06-25
Last Posted Date
2025-03-11
Lead Sponsor
Leuko Labs, Inc.
Target Recruit Count
100
Registration Number
NCT04448301
Locations
🇺🇸

Boston Medical Center, Boston, Massachusetts, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.